Carocell Bio

Carocell Bio is a pre-clinical stage biotechnology company developing proprietary peptide-based therapeutics for inflammatory diseases.

Its pipeline centres on topical formulations that inhibit mitogen-activated protein kinase (MAPK/p38), a key regulator of the inflammatory cascade. Lead programmes target atopic dermatitis, inflammatory bowel disease, burns and scarring.

Candidates are formulated using nanoparticle delivery systems to enhance skin penetration, and have demonstrated activity in human biopsy studies.